| Background:Bladder cancer is one of the most common urinary tract epithelial tumors,ranking tenth in the world’s most common malignant tumors.Its incidence and mortality rates are still relatively high.With the continuous deepening of research,it has been found that the occurrence and development of bladder cancer is a multi-mechanism process,and the molecular mechanism of its occurrence and development is still unclear.ATP-binding cassette subfamily F member 1(ABCF1)is a member of the ATP-binding cassette transporter family,and previous studies have found that it is highly expressed in various malignant tumor tissues and participates in tumor occurrence and developmentresearch.However,the role of ABCF1 in bladder cancer is still unclear.In this study,we explored the expression and clinical significance of ABCF1 in bladder cancer through bioinformatics analysis and external experiments.This is of great significance for discovering new therapeutic targets for bladder cancer and predicting new prognostic markers for bladder cancer,providing new ideas for the precise diagnosis and treatment of bladder cancer.Methods:In this study,we first collected gene expression data of 19 normal bladder tissues and 414 bladder cancer tissues from the Cancer Genome Atlas(TCGA)and the gene expression comprehensive database(GEO)GSE13507 dataset.The Wilcoxon rank-sum test was used to analyze the expression difference of ABCF1 between bladder cancer tissue and normal tissue.The differential expression of ABCF1 in bladder cancer cell lines was further verified by real-time fluorescence quantitative PCR(q RT-PCR)and western blot(WB).The Human Protein Atlas(HPA)database was used to explore the expression pattern of ABCF1 in bladder cancer tissues,and its expression in bladder cancer tissue and normal bladder tissue was further verified by immunohistochemistry(IHC).The correlation between ABCF1 expression levels and the prognosis of bladder cancer patients was analyzed using the expression data and follow-up information from the TCGA dataset,and further verified using clinical data from 60 bladder cancer patients in our hospital.Gene Set Enrichment Analysis(GSEA)was used to determine the potential signaling pathways associated with ABCF1 and explore the mechanism of ABCF1 in the development of bladder cancer.The relationship between ABCF1 expression and the progression of bladder cancer was analyzed using the GSE13507 dataset.Results:In this study,we found that ABCF1 was highly expressed in bladder cancer tissue(P < 0.0001).The expression level of ABCF1 was higher in female bladder cancer patients(P = 0.00056),higher in bladder cancer patients with higher pathological grades(P = 0.00049),and higher in patients with bladder cancer invading the muscle layer(T2-T4)than in those without muscle layer invasion(Ta and T1)(P=0.00007).The expression level of ABCF1 was also higher in bladder cancer patients with distant metastasis(N classification)than in those without distant metastasis(P = 0.0076).High expression of ABCF1 was positively correlated with poor prognosis of bladder cancer patients(P < 0.001).In addition,univariate and multivariate Cox regression analysis showed that high expression of ABCF1 was an independent risk factor for poor prognosis of bladder cancer patients.q RT-PCR and WB showed that ABCF1 was highly expressed in bladder cancer cell lines,IHC showed that ABCF1 expression was elevated in bladder cancer tissue,and survival analysis showed that patients with high ABCF1 expression had a poorer prognosis.Conclusion:The results of this study indicate that ABCF1 is highly expressed in bladder cancer tissues and its expression level is related to clinical staging and grading of bladder cancer,and is positively correlated with poor prognosis of bladder cancer patients.Therefore,ABCF1 plays an important role in the progression of bladder cancer and is a potential therapeutic target and prognostic marker for predicting poor prognosis of bladder cancer. |
PDF Full Text Request